Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4799695
Max Phase: Preclinical
Molecular Formula: C76H121N21O19
Molecular Weight: 1632.93
Molecule Type: Unknown
Associated Items:
ID: ALA4799695
Max Phase: Preclinical
Molecular Formula: C76H121N21O19
Molecular Weight: 1632.93
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N)C(=O)N[C@@H](CC(C)C)C(=O)O
Standard InChI: InChI=1S/C76H121N21O19/c1-8-42(6)61(71(112)94-56(74(115)116)36-41(4)5)95-68(109)54(38-45-22-26-47(99)27-23-45)93-70(111)58-19-14-34-97(58)73(114)51(17-12-32-85-76(82)83)88-63(104)48(16-11-31-84-75(80)81)87-69(110)57-18-13-33-96(57)72(113)50(15-9-10-30-77)89-67(108)55(39-59(79)100)92-64(105)49(28-29-60(101)102)86-66(107)53(37-44-20-24-46(98)25-21-44)91-65(106)52(35-40(2)3)90-62(103)43(7)78/h20-27,40-43,48-58,61,98-99H,8-19,28-39,77-78H2,1-7H3,(H2,79,100)(H,86,107)(H,87,110)(H,88,104)(H,89,108)(H,90,103)(H,91,106)(H,92,105)(H,93,111)(H,94,112)(H,95,109)(H,101,102)(H,115,116)(H4,80,81,84)(H4,82,83,85)/t42-,43-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,61-/m0/s1
Standard InChI Key: LJDKIRQGXSOPEQ-JYDDPDNISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1632.93 | Molecular Weight (Monoisotopic): 1631.9148 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Chartier M,Desgagné M,Sousbie M,Côté J,Longpré JM,Marsault E,Sarret P. (2021) Design, Structural Optimization, and Characterization of the First Selective Macrocyclic Neurotensin Receptor Type 2 Non-opioid Analgesic., 64 (4.0): [PMID:33538583] [10.1021/acs.jmedchem.0c01726] |
Source(1):